LXA4 attenuates liver fibrosis by suppressing TNF-α, IFN-γ, IL-2, and IL-17 and augmenting IL-4 and IL-10 production [103], implying that LXA4 and its precursor AA may be of benefit in preventing the lung fibrosis seen in some patients with COVID-19 (termed as long-haulers). This evidence concerns the gene TNF and COVID-19.